| Semaglutide | Tirzepatide | Retatrutide --- | --- | --- | --- Receptors | GLP-1 only | GLP-1 + GIP | GLP-1 + GIP + Glucagon FDA Status | Approved | Approved | Not approved (Phase 3 trials) Avg. Weight Loss | ~15% | ~20% | ~24% Side Effect Profile | More GI sides | Fewer GI sides | Variable; may affect heart rate Brand Names | Ozempic, Wegovy | Mounjaro, Zepbound | None (investigational) Gray Market Cost | Cheapest | Moderate | ~2× tirz price